Actively Recruiting
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
Led by Alexandria University · Updated on 2025-03-26
100
Participants Needed
1
Research Sites
28 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to assess the effect of finerenone on proteinuria and GFR progression in patients with non-diabetic glomerulonephritis.
CONDITIONS
Official Title
Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-proven glomerulonephritis patients on maximum tolerated doses of ACE inhibitors or ARBs plus immunosuppression if needed for at least 4 weeks
- Urinary protein excretion greater than 500 mg/g
- Adults aged 18 years and older
- Estimated glomerular filtration rate (eGFR) of 25 mL/min/1.73 m2 or higher
- Baseline serum potassium level below 5 mEq/L
You will not qualify if you...
- Diabetes mellitus (type 1 or 2)
- Other non-glomerular kidney diseases
- Heart failure
- Pregnancy or breastfeeding
- Use of hyperkalemia treatments within 4 weeks before study
- Uncontrolled high blood pressure (greater than 160/100)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of Medicine, Aexandria University
Alexandria, Egypt, 21526
Actively Recruiting
Research Team
M
Mohamed Mamdouh Elsayed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here